Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Light Sciences Oncology has raised $40.1 million in a series C round of financing. The company raised $97 million in its first two rounds of financing.
Subscribe to our email newsletter
Light Sciences Oncology (LSO) plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients with hepatocellular carcinoma and metastatic colorectal cancer, a planned Phase III trial in glioblastoma multiforme, and early stage clinical trials in benign prostatic hyperplasia.
Leerink Swann acted as exclusive placement agent and exclusive financial advisor in connection with the transaction.
Llew Keltner, president and CEO of LSO, said: “The series C funds combined with our substantial cash reserves will allow us to continue to move forward with all aspects of our development plan in a timely manner.”